These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 31832851)

  • 1. Sorafenib may enhance antitumour efficacy in hepatocellular carcinoma patients by modulating the proportions and functions of natural killer cells.
    Hu J; Wang E; Liu L; Wang Q; Xia D; Bai W; Tie J; Li X; Yuan J; Yang S; Jiang D; Shi J; Sun Y; Wang J; Zhang C; Niu J; Li K; He C; Guo W; Lv Y; Chen H; Yuan X; Yu T; Wang Z; Luo B; Han N; Zhu Y; Yin Z; Fan D; Zhang Z; Yang K; Han G
    Invest New Drugs; 2020 Oct; 38(5):1247-1256. PubMed ID: 31832851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sorafenib attenuated the function of natural killer cells infiltrated in HCC through inhibiting ERK1/2.
    Li C; Wei S; Xu X; Jiang Y; Xue L; Jiang P; Wang J
    Int Immunopharmacol; 2019 Nov; 76():105855. PubMed ID: 31472321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Percentages and functions of natural killer cell subsets in peripheral blood of patients with severe aplastic anemia].
    Li ZS; Shao ZH; Fu R; Wang J; Li LJ; Zhang T; Wang HQ; Wu YH; Ruan EB; Song J; Qu W; Liu H; Xing LM; Wang XM; Liang Y; Guan J; Wang GJ
    Zhonghua Yi Xue Za Zhi; 2011 Apr; 91(16):1084-7. PubMed ID: 21609587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib.
    Meyer T; Palmer DH; Cheng AL; Hocke J; Loembé AB; Yen CJ
    Liver Int; 2017 Jul; 37(7):1047-1055. PubMed ID: 28066978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD56
    Vujanovic L; Chuckran C; Lin Y; Ding F; Sander CA; Santos PM; Lohr J; Mashadi-Hossein A; Warren S; White A; Huang A; Kirkwood JM; Butterfield LH
    Front Immunol; 2019; 10():14. PubMed ID: 30761123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive characterization of tumor infiltrating natural killer cells and clinical significance in hepatocellular carcinoma based on gene expression profiles.
    Wu M; Mei F; Liu W; Jiang J
    Biomed Pharmacother; 2020 Jan; 121():109637. PubMed ID: 31810126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD3(-)CD16(-)CD56(bright) immunoregulatory NK cells are increased in the tumor microenvironment and inversely correlate with advanced stages in patients with papillary thyroid cancer.
    Gogali F; Paterakis G; Rassidakis GZ; Liakou CI; Liapi C
    Thyroid; 2013 Dec; 23(12):1561-8. PubMed ID: 23721357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of CD16+ CD56bright NK cells with antitumour cytotoxicity not only from CD16- CD56bright NK Cells but also from CD16- CD56dim NK cells.
    Takahashi E; Kuranaga N; Satoh K; Habu Y; Shinomiya N; Asano T; Seki S; Hayakawa M
    Scand J Immunol; 2007 Feb; 65(2):126-38. PubMed ID: 17257217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Characteristics of peripheral NK cells in hepatocellular carcinoma patients].
    Zhou L; Cai L; Zhang Z; Yang YP; Wang FS
    Zhonghua Gan Zang Bing Za Zhi; 2010 Feb; 18(2):136-9. PubMed ID: 20196954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diminished absolute counts of CD56dim and CD56bright natural killer cells in peripheral blood from Egyptian patients with hepatocellular carcinoma.
    Fathy A; Eldin MM; Metwally L; Eida M; Abdel-Rehim M
    Egypt J Immunol; 2009; 16(2):17-25. PubMed ID: 22059350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells.
    Sprinzl MF; Reisinger F; Puschnik A; Ringelhan M; Ackermann K; Hartmann D; Schiemann M; Weinmann A; Galle PR; Schuchmann M; Friess H; Otto G; Heikenwalder M; Protzer U
    Hepatology; 2013 Jun; 57(6):2358-68. PubMed ID: 23424039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sorafenib plus memory-like natural killer cell immunochemotherapy boosts treatment response in liver cancer.
    Eresen A; Zhang Z; Yu G; Hou Q; Chen Z; Yu Z; Yaghmai V; Zhang Z
    BMC Cancer; 2024 Sep; 24(1):1215. PubMed ID: 39350084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ERK1/2, MEK1/2 and p38 downstream signalling molecules impaired in CD56 dim CD16+ and CD56 bright CD16 dim/- natural killer cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients.
    Huth TK; Staines D; Marshall-Gradisnik S
    J Transl Med; 2016 Apr; 14():97. PubMed ID: 27098723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD56
    Wang H; Zeng Y; Zhang M; Ma H; Xu B; Jiang H; Wang J; Li G
    Hum Immunol; 2019 Oct; 80(10):871-877. PubMed ID: 31326139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Augmentation of IFN-γ+ CD8+ T cell responses correlates with survival of HCC patients on sorafenib therapy.
    Kalathil SG; Hutson A; Barbi J; Iyer R; Thanavala Y
    JCI Insight; 2019 Aug; 4(15):. PubMed ID: 31391334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma.
    Goyal L; Zheng H; Abrams TA; Miksad R; Bullock AJ; Allen JN; Yurgelun MB; Clark JW; Kambadakone A; Muzikansky A; Knowles M; Galway A; Afflitto AJ; Dinicola CF; Regan E; Hato T; Mamessier E; Shigeta K; Jain RK; Duda DG; Zhu AX
    Clin Cancer Res; 2019 Jan; 25(1):80-89. PubMed ID: 30190369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating NK cells and their subsets in Behçet's disease.
    Hasan MS; Ryan PL; Bergmeier LA; Fortune F
    Clin Exp Immunol; 2017 May; 188(2):311-322. PubMed ID: 28170096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human CD56
    Amand M; Iserentant G; Poli A; Sleiman M; Fievez V; Sanchez IP; Sauvageot N; Michel T; Aouali N; Janji B; Trujillo-Vargas CM; Seguin-Devaux C; Zimmer J
    Front Immunol; 2017; 8():699. PubMed ID: 28674534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early Cytomegalovirus Reactivation and Expansion of CD56
    Jang JE; Hwang DY; Chung H; Kim SJ; Eom JI; Jeung HK; Song J; Kim JS; Cheong JW; Min YH
    Biol Blood Marrow Transplant; 2019 Oct; 25(10):2070-2078. PubMed ID: 31212079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expansion of circulating CD56bright natural killer cells in patients with JAK2-positive chronic myeloproliferative neoplasms during treatment with interferon-α.
    Riley CH; Hansen M; Brimnes MK; Hasselbalch HC; Bjerrum OW; Straten PT; Svane IM; Jensen MK
    Eur J Haematol; 2015 Mar; 94(3):227-34. PubMed ID: 25082025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.